To provide the information your oncologist is not telling you or doesn't have the time to!
On November 20, 2024, the FDA granted accelerated approval to zanidatamab-hrii (Ziihera), a bispecific HER2-directed antibody, for the treatment of previously treated, unresectable, or metastatic HER2-positive biliary tract cancer (BTC). This decision brings new hope for patients battling this aggressive and hard-to-treat disease, offering a targeted option for a population with limited therapeutic choices. The …
Small-cell lung cancer (SCLC) is a notoriously aggressive form of lung cancer, making up about 15% of all lung cancer cases. While treatments have made strides in extensive-stage SCLC, limited-stage SCLC has seen few advancements in decades—until now. A new clinical trial published in the New England Journal of Medicine has revealed promising results with the use …
by Sajeve Thomas, MD, Oncologist Biliary tract cancer (BTC), a rare and aggressive form of cancer affecting the bile ducts, gallbladder, and liver, has historically been challenging to treat. However, there is hope on the horizon with the recent FDA approval of pembrolizumab (Keytruda, Merck) in combination with chemotherapy. This groundbreaking development offers new possibilities …